Vimarsana
Biggest News Aggregation in the World

Page 4 - Pharma Partnering News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Partnering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Partnering Today - Breaking & Trending Today

Roche, Genentech, Recursion Launch Up-to-$12B AI Drug Discovery Effort - Vimarsana News

Roche, Genentech, Recursion Launch Up-to-$12B AI Drug Discovery Effort

Roche and its Genentech subsidiary have committed up to $12 billion to Recursion in return for using its Recursion Operating System (OS) to advance therapies in 40 programs that include “key areas” of neuroscience and an undisclosed oncology indication.

Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech - Vimarsana News

Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech

Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech ACCESSWIRE 25 May 2021, 22:05 GMT+10 Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs Collaboration includes initial programs in respiratory disease and ophthalmology, with opportunity to nominate additional programs BOSTON, MA / ACCESSWIRE / May 25, 2 021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biother...

Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics - Vimarsana News

Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics

Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics Ribometrix, Inc., today announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets. Ribometrix is focused on leveraging its RNA structural expertise and analytical capabilities to make the vast landscape of RNA, which is involved in a wide variety ...

Genentech Launches $1B+ RNA Collaboration with Ribometrix - Vimarsana News

Genentech Launches $1B+ RNA Collaboration with Ribometrix

Genentech Launches $1B+ RNA Collaboration with Ribometrix Ribometrix has shown that several RNAs associated with disease contain structural pockets—clefts and crevices (highlighted)—that are amenable to targeting with small molecules. Genentech, a member of the Roche Group, will apply Ribometrix’s discovery platform to discover, develop and commercialize small molecule drug candidates against RNA targets, through a collaboration that could generate more than $1 billion for the Durham, NC-based company. [Ribometrix] January 6, 2021 Ribometrix has shown that several RNAs associated with ...